Gilbert Douglas, DO
Internal Medicine · Gardendale, ALNPI 1881865103
Payments from drug & device makers
Across 100 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$507
- Lilly USA, LLC$226
- GSK$194
- Irhythm Technologies, Inc.$180
- AstraZeneca$133
- Amgen$103
- plus $606 from 15 others
What the payments were for
- Food & beverage$1,948100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $507 |
| Lilly USA, LLC | 12 | $226 |
| GSK | 10 | $194 |
| Irhythm Technologies, Inc. | 4 | $180 |
| AstraZeneca | 7 | $133 |
| Amgen(2 entities) | 6 | $103 |
| Pfizer | 6 | $96 |
| Exact Sciences | 6 | $87 |
| Phathom Pharmaceuticals, Inc. | 4 | $66 |
| Shield Therapeutics Inc | 3 | $55 |
| Dexcom, Inc. | 2 | $46 |
| Currax Pharmaceuticals LLC | 3 | $46 |
| AbbVie | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Novartis | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Atland Pharmaceuticals, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zio monitor$125
- ZIO XT Patch$125
How this compares
$1,948 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 245 | $185,466 |
| OzempicSemaglutide | 112 | $150,260 |
| MounjaroTirzepatide | 105 | $130,514 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $60,187 |
| XareltoRivaroxaban | 59 | $59,419 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $40,471 |
| JanuviaSitagliptin Phosphate | 39 | $27,001 |
| JardianceEmpagliflozin | 30 | $24,624 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $19,384 |
| FarxigaDapagliflozin Propanediol | 30 | $19,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,162 |
| TrulicityDulaglutide | 12 | $18,916 |
| LinzessLinaclotide | 27 | $16,043 |
| Atorvastatin Calcium | 746 | $12,284 |
| Levothyroxine Sodium | 636 | $10,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $185,466245 claims |
| Novo NordiskOzempic | $507 | $150,260112 claims |
| Lilly USA, LLCMounjaro, Trulicity | $226 | $149,430117 claims |
| Johnson & JohnsonXarelto | $14 | $59,41959 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $133 | $33,12169 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $194 | $29,48756 claims |
| AbbVieLinzess, Synthroid | $40 | $21,81886 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Gardendale
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.